{"id":8263,"date":"2022-05-06T09:30:00","date_gmt":"2022-05-06T09:30:00","guid":{"rendered":"https:\/\/www.acarix.com\/acarix-presents-at-naventus-health-care-summit-2022-2\/"},"modified":"2024-11-18T19:05:30","modified_gmt":"2024-11-18T19:05:30","slug":"acarix-presents-at-naventus-health-care-summit-2022-2","status":"publish","type":"post","link":"https:\/\/d.ptpl.dev\/acarix\/acarix-presents-at-naventus-health-care-summit-2022-2\/","title":{"rendered":"Acarix presents at Naventus Health Care Summit 2022"},"content":{"rendered":"
\n

Press release<\/strong> <\/strong>
Malmö, Sweden, May 6, 2022  <\/p>\n

Acarix presents at <\/strong>Naventus<\/strong> Health Care Summit 2022<\/strong><\/p>\n

Helen Ljungdahl Round, President and CEO of Acarix AB (<\/strong>publ<\/strong>), will present at the <\/strong>Naventus<\/strong> Health Care Summit in Stockholm on May 10, 2022.<\/strong><\/p>\n

Acarix is one of twelve leading companies within the Healthcare sector to present their views on the present trends in precision medicine and latest innovative technological developments in life science.<\/p>\n

Acarix is at the forefront of AI-powered acoustic diagnostic technologies in cardiology. The novel CADScor®System is designed for rapid assessment in patients with stable chest pain and suspected CAD. Within 10 minutes, those with low risk can be ruled out with 96% certainty. Millions of people experience chest pain annually and many undergo lengthy diagnostic assessments. As many as 9 out of 10 are found to not have CAD, putting an unnecessary burden on the health care systems and patients. The CADScor®System has CE-marking and is commercially available in Europe. With the FDA De Novo clearance and reimbursement approval, the company is now entering a new expansion phase with the launch in the US.<\/p>\n

This event is a perfect opportunity to learn about the latest market updates technological innovations within the Healthcare sector. The event is hosted by Naventus & Partners live from Spegelsalen, Grand Hôtel in Stockholm with opportunities to join virtually.<\/p>\n

Learn more about Acarix and CADScor®System here<\/a>.
Sign up for the event here<\/a>.<\/p>\n

For more information contact:<\/strong> 
Helen Ljungdahl Round, CEO,phone +1 267 809 1225,+46 730 770283 helen.round@acarix.com <\/p>\n

The information was provided, through the agency of the above contact person, for publication at the time specified by the company’s news distributor, GlobeNewswire.<\/em><\/p>\n

About Acarix:<\/strong> 
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor®System calculates a patient-specific CAD-score non-invasively in less than 10 minutes and can help rule out more than one third of patients with at least 96% certainty (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com.<\/p>\n

\n

\n <\/div>\n

\n

Attachments<\/strong><\/p>\n

\n

PR_Acarix Naventus HC 2022_eng.<\/a><\/p>\n<\/div>\n

<\/div>\n